A Strategy Inc. Business Plan is selected by global lifescience 1) companies with a novel technology seeking funding or exit, 2) entities attempting to prioritize between opportunities to determine those with the highest return on investment, and 3) companies seeking a commercialization road map that outlines the path with the highest potential for success.

A Strategy Inc. Business Plan is a customized comprehensive assessment that covers a broad scope of global business analyses.

• The Market Assessment defines the potential for commercial success for each of the identified target markets.
• The Competitive Analysis facilitates the identification and assessment of a potential market "space", product positioning and feature set identification for a selected product.
• The Clinical Assessment determines the projected clinical adoption based on one-on-one interviews with global opinion leaders and in-the-trenches physicians.
• The Current Reimbursement Landscape Analysis determines reimbursement surrounding the particular device or biologic including product coverage, coding, payment and financial impact.
  
  
  
  Click above to see a Reimbursement example


• The Risk Analysis outlines the most direct path to successful commercialization while mitigating the known and potential risks of product development.
• The Financial Analysis includes a ProForma with five to ten year revenue projections based on a risk adjusted bottoms-up sales analysis which includes a projected product adoption, a pricing matrix and projected cost of goods forecasts.
  
  
  
  Click above to see a Financial Analysis example